title: A comparison of the ability of the human IgG1 allotypes G1m3 and G1m1,17 to stimulate T-cell responses from allotype matched and mismatched donors.
abstract: The immunogenicity of clinically administered antibodies has clinical implications for the patients receiving them, ranging from mild consequences, such as increased clearance of the drug from the circulation, to life-threatening effects. The emergence of methods to engineer variable regions resulting in the generation of humanised and fully human antibodies as therapeutics has reduced the potential for adverse immunogenicity. However, due to differences in sequence referred to as allotypic variation, antibody constant regions are not homogeneous within the human population, even within sub-classes of the same immunoglobulin isotype. For therapeutically administered antibodies, the potential exists for an immune response from the patient to the antibody if the allotype of patient and antibody do not match. Allotypic distribution in the human population varies within and across ethnic groups making the choice of allotype for a therapeutic antibody difficult. This study investigated the potential of human IgG1 allotypes to stimulate responses in human CD4(+) T cells from donors matched for homologous and heterologous IgG1 allotypes. Allotypic variants of the therapeutic monoclonal antibody trastuzumab were administered to genetically defined allotypic matched and mismatched donor T cells. No significant responses were observed in the mismatched T cells. To investigate the lack of T-cell responses in relation to mismatched allotypes, HLA-DR agretopes were identified via MHC associated peptide proteomics (MAPPs). As expected, many HLA-DR restricted peptides were presented. However, there were no peptides presented from the sequence regions containing the allotypic variations. Taken together, the results from the T-cell assay and MAPPs assay indicate that the allotypic differences in human IgG1 do not represent a significant risk for induction of immunogenicity.
authors.affiliation: a MedImmune Ltd, Milstein Building , Granta Park, Cambridge , CB21 6GH , United Kingdom.
authors.forename: Carl I
authors.initials: CI
authors.lastname: Webster
authors.affiliation: b Antitope Ltd (An Abzena company), Babraham Research Campus , Babraham, Cambridge , CB22 3AT , United Kingdom.
authors.forename: Christine J
authors.initials: CJ
authors.lastname: Bryson
authors.affiliation: b Antitope Ltd (An Abzena company), Babraham Research Campus , Babraham, Cambridge , CB22 3AT , United Kingdom.
authors.forename: Edward A
authors.initials: EA
authors.lastname: Cloake
authors.affiliation: b Antitope Ltd (An Abzena company), Babraham Research Campus , Babraham, Cambridge , CB22 3AT , United Kingdom.
authors.forename: Tim D
authors.initials: TD
authors.lastname: Jones
authors.affiliation: a MedImmune Ltd, Milstein Building , Granta Park, Cambridge , CB21 6GH , United Kingdom.
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Austin
authors.affiliation: c Novartis Pharma AG , Klybeckstrasse 141, CH-4057 Basel , Switzerland.
authors.forename: Anette C
authors.initials: AC
authors.lastname: Karle
authors.affiliation: c Novartis Pharma AG , Klybeckstrasse 141, CH-4057 Basel , Switzerland.
authors.forename: Sebastian
authors.initials: S
authors.lastname: Spindeldreher
authors.affiliation: a MedImmune Ltd, Milstein Building , Granta Park, Cambridge , CB21 6GH , United Kingdom.
authors.forename: David C
authors.initials: DC
authors.lastname: Lowe
authors.affiliation: b Antitope Ltd (An Abzena company), Babraham Research Campus , Babraham, Cambridge , CB22 3AT , United Kingdom.
authors.forename: Matthew P
authors.initials: MP
authors.lastname: Baker
mesh_terms: D001782:Blood Donors; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D005260:Female; D006684:HLA-DR Antigens / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology*; D007129:Immunoglobulin Gm Allotypes / Q000276:immunology*
chemical_list: D006684:HLA-DR Antigens; D007074:Immunoglobulin G; D007129:Immunoglobulin Gm Allotypes
keywords: Allotype; Epitope; HLA; IgG; Immunogenicity; MAPPs; MHC; T-cell
references.citation: MAbs. 2010 May-Jun;2(3):256-65
references.pmid: 20400861
references.citation: Nat Immunol. 2002 Jan;3(1):61-8
references.pmid: 11743588
references.citation: Science. 1963 Feb 1;139(3553):418-9
references.pmid: 14012122
references.citation: Curr Drug Saf. 2010 Oct;5(4):272-4
references.pmid: 20925649
references.citation: Science. 1964 Jul 10;145(3628):170-1
references.pmid: 14171557
references.citation: Drugs R D. 2008;9(6):385-96
references.pmid: 18989990
references.citation: Biochem J. 1970 May;117(4):641-60
references.pmid: 5449120
references.citation: Nat Rev Drug Discov. 2007 May;6(5):349-56
references.pmid: 17431406
references.citation: Curr Opin Drug Discov Devel. 2007 Mar;10(2):219-27
references.pmid: 17436557
references.citation: J Exp Med. 1966 Oct 1;124(4):715-32
references.pmid: 4162448
references.citation: Acta Rheumatol Scand. 1956;2(4):55-8
references.pmid: 13424354
references.citation: Proc Natl Acad Sci U S A. 1964 Jun;51:1007-14
references.pmid: 14218064
references.citation: Nature. 1986 May 29-Jun 4;321(6069):522-5
references.pmid: 3713831
references.citation: Methods. 2005 May;36(1):3-10
references.pmid: 15848070
references.citation: Proc Natl Acad Sci U S A. 1984 Nov;81(21):6851-5
references.pmid: 6436822
references.citation: J Immunol. 1976 Sep;117(3):1056-8
references.pmid: 956649
references.citation: Dev Comp Immunol. 2005;29(3):185-203
references.pmid: 15572068
references.citation: PLoS One. 2014 Jan 21;9(1):e86322
references.pmid: 24466023
references.citation: Clin Immunol Immunopathol. 1977 Jan;7(1):97-113
references.pmid: 404106
references.citation: Gene. 1997 Mar 10;187(1):9-18
references.pmid: 9073061
references.citation: Arthritis Res Ther. 2010;12(6):R221
references.pmid: 21187010
references.citation: MAbs. 2009 Jul-Aug;1(4):332-8
references.pmid: 20073133
references.citation: Nat Rev Immunol. 2010 May;10(5):301-16
references.pmid: 20414204
references.citation: Cancer Res. 2005 Nov 1;65(21):10068-78
references.pmid: 16267033
references.citation: Nat Biotechnol. 2005 Sep;23(9):1117-25
references.pmid: 16151405
references.citation: Proc Natl Acad Sci U S A. 1992 May 15;89(10):4285-9
references.pmid: 1350088
references.citation: Nature. 1990 Dec 6;348(6301):552-4
references.pmid: 2247164
references.citation: Nature. 1975 Aug 7;256(5517):495-7
references.pmid: 1172191
references.citation: J Thromb Haemost. 2005 May;3(5):991-1000
references.pmid: 15869596
references.citation: Genes Immun. 2011 Apr;12(3):213-21
references.pmid: 21326320
references.citation: C R Hebd Seances Acad Sci. 1956 May 23;242(21):2606-8
references.pmid: 13343562
references.citation: Exp Clin Immunogenet. 1989;6(1):7-17
references.pmid: 2698222
references.citation: Nature. 1988 Mar 24;332(6162):323-7
references.pmid: 3127726
references.citation: Pharmacogenet Genomics. 2009 May;19(5):383-7
references.pmid: 19319024
references.citation: Science. 1963 Apr 19;140(3564):303-4
references.pmid: 13983708
references.citation: J Immunotoxicol. 2006 Sep 1;3(3):131-6
references.pmid: 18958693